Background: Brugada syndrome (BrS) is associated with sudden cardiac death (SCD).
| INTRODUCTION
Type I Brugada syndrome (BrS) is presented by a right bundle branch block (RBBB) and coved ST-segment elevation in precordial leads (V1-V3), and its clinical relevance lies in the fact that patients have a pronounced risk to develop malignant tachyarrhythmias. 1, 2 The prevalence of BrS is estimated to be 5/10 000 inhabitants with a higher prevalence in Japan and Philippines as compared to western countries. Not considering accidents, BrS is the leading cause of death in men <40 years old, particularly in countries where the syndrome is endemic. Fever and sodium-channel blockers could potentially unmask BrS, which have led to an expert consensus advising patients with BrS to avoid these drugs and express caution during clinical states such as fever and infections. 3 Due to the high risk of sudden cardiac death (SCD), it has been recommended that BrS-patients with a previous episode of sudden cardiac arrest, or those showing inducibility of a sustained ventricular arrhythmia during an electrophysiological study be treated with an implantable cardioverter-defibrillator (ICD). 4 However, ICD is not always feasible or adequate for every patient.
Although alternative treatments including hydroquinine (HQ) treatment and catheter ablation therapy have demonstrated efficacy in recurrent ventricular arrhythmias, 5 patients who have experienced a prior cardiac arrest or syncopal events secondary to ventricular tachycardia/ventricular fibrillation should undergo ICD implantation. 6, 7 ICD implantation for primary prevention in BrS patients is controversial. 6, 8 The aim of the present study is to observe the long-term outcome and complication rate of BrS patients, who have received transvenous ICD implantation for primary and secondary prevention.
| METHODS
In this analysis, we included all patients diagnosed with BrS and treated with transvenous ICD implantation 2007 and 2018. A total of 747 BrS patients described in 11 research papers, were recruited for our analysis.
BrS was diagnosed only in the presence of a type 1 Brugada pattern on the electrocardiogram (ECG) (coved type), either at baseline or after the administration of a sodium channel blocking agent. The definition of type 1 ECG pattern was the presence of a terminal r 0 -wave with a J-point elevation of at least 0.2 mV, with a slowly descending ST-segment followed by a negative T-wave in ≥1 right precordial lead
. ECG is placed in the fourth, third, or second intercostal space.
Sodium channel blockers were administered intravenously over a 10-minutes period to unmask the diagnostic ECG pattern of BrS in case of a non-type 1 ECG pattern at baseline. Programming of ICDs of included studies is summarized in Table S1. Patients were followed annually in a dedicated cardiogenetic outpatient clinic and every 6 to 12 months in the ICD clinic (unless shorter periods of follow-up were required).
| Data collection of different studies
Demographic and clinical data including age at diagnosis, gender, family history of SCD or BrS, symptoms before diagnosis, such as atrial arrhythmias and syncope, results of drug testing, affected genotype, electrophysiological study including ventricular stimulation were followed-up and evaluated. Baseline ICD-related data included type of ICD. The indication for ICD implantation was reviewed in different studies, with emphasis on basal ECG characteristics, history of recurrent syncope, inducible VT of VF during programmed ventricular stimulation (PVS), family history of SD, and history of VF or aborted cardiac arrest. 
| Systematic literature review

| Statistics
Data are presented as mean ± SD for continuous variables with a nor- 
| Demographics
The mean age of patients receiving ICD was 43.1 ± 13.4 with a predominance of males (82.5%). 46.6% of patients showed spontaneous BrS type I and 50.3% demonstrated BrS type I after use of an intravenous sodium channel blocker. Only 21.7% of the patients were asymptomatic. Symptoms were documented as following: 48.3% suffered from recurrent syncope, 15.5% admission due to SCD, and 10.4% atrial arrhythmia, Table S2 .
An electrophysiological study (EP) and PVS was performed in 247 patients to study the inducibility of ventricular tachycardia/ventricular fibrillation, and this was documented in 171 patients (69.2% of cases). Table 1 and Figure 2B . Also 3.2% of the patients suffered from an electrical storm. We have compared the data of inappropriate ICD shocks regarding in asymptomatic and symptomatic patients. Asymptomatic BrS patients suffered more significantly from lower rate of inappropriate shocks (Figure 3 A,B ). On the other hand, appropriate ICD shocks were significantly more documented in symptomatic patients (Figure 4 A,B ).
| ICD-related complications
| Management of complications
Pulmonary vein isolation was carried out in 0.5% of the patients. About 1.3% received drug treatment with sotalol or sotalol with beta-blocker (0.3%) and 0.1% received HQ. Electrical storm was documented in 24 patients (3.2%). Therefore, 21 (2.8%) patients were treated with HQ to manage electrical storm, Table 1 and ICD therapy is suggested in survivors of SCD, 6 however, data have suggested that its use may be associated with significant Overall, there is great variation in the reported rate of appropriate therapy in BrS patients. One of the most significant differences between these studies are the incidence of appropriate therapies in previously asymptomatic individuals. Although several authors report no therapy in this group, during an average follow-up of 2.3 to 7.3 years, 12, 13, [23] [24] [25] other studies report an overall rate of 4% to 13% after an average follow-up of 3.2 to 9.3 years. 9,15,26-28 A difference in the study population is the most likely explanation for this observation. Although inappropriate ICD shocks were more documented in symptomatic patients, even more appropriate ICD shocks were also more documented in this group.
BrS and short QT syndrome may be considered similar entities, 29 thus, comparing patient data from these two groups could prove interesting. Whereas in short QT syndrome, inappropriate therapy is more inherent due to the detection of short-coupled and prominent T waves (in up to 60% of cases); in BrS, supraventricular arrhythmias are often responsible for the inappropriate shocks. Therefore, careful testing of ICD function and adaptation of sensing levels and decay delays without sacrificing correct arrhythmia detection might be essential for short QT syndrome patient. 30 On the other hand, in BrS, drug treatment and ablation strategies might be more useful to manage inappropriate shocks. 31, 32 Although only 15.3% of patients were admitted due to aborted out of hospital cardiac arrest and these received ICD implantations for secondary prevention, asymptomatic patients receiving ICDs for primary prevention also suffered from life-threatening arrhythmias, which were terminated by appropriate ICD shocks. However, further insights in risk stratification strategies are necessary in BrS to avoid ICD-related complications.
| Study limitation
This study provides registry data dominated by retrospective studies and, although the authors clinically evaluated all patients, clinical assessment and treatment algorithm was not uniform and consecutively ICD indications were homogeneous throughout the study. Only SCN5A mutations were evaluated in the present analysis; excluding the possibility of mutations in other BrS-related genes. Also, despite the obvious advantages of our recruited studies, novel therapeutic approaches like ventricular ablation and systematic use of HQ were not evaluated. Finally, the role of subcutaneous ICD was not evaluated in the present study.
| CONCLUSIONS
Regarding a relevant risk of device-related complications with a higher rate of inappropriate ICD shocks in symptomatic BrS patients special care during regular follow-up in specialized cardiogenetic centers may allow the reduction in the number of adverse events.
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